Seeking Alpha

An FDA panel has voted 3-14 that Abbott (ABT) has not found right dose for its irritable bowel...

An FDA panel has voted 3-14 that Abbott (ABT) has not found right dose for its irritable bowel syndrome drug Humira. Last week, FDA staff had questioned whether Humira had a real benefit for people with the disease who had already tried other treatments.
Comments (2)
  • alexcampbello
    , contributor
    Comments (247) | Send Message
     
    share up 0.11 !!!!!!!!!!
    28 Aug 2012, 02:25 PM Reply Like
  • popster76
    , contributor
    Comments (213) | Send Message
     
    IBS or irritable bowel syndrome is a completely different condition from IBD or Inflammatory Bowel Disease. IBD consists of Crohn's Disease as well as Ulcerative Colitis, for which Humira was attempting to obtain another indication.
    28 Aug 2012, 03:06 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector